Vivo Ventures Fund Vi, L.p. - Net Worth and Insider Trading
Vivo Ventures Fund Vi, L.p. Net Worth
The estimated net worth of Vivo Ventures Fund Vi, L.p. is at least $76 Million dollars as of 2024-11-13. Vivo Ventures Fund Vi, L.p. is the 10% Owner of Sagent Pharmaceuticals Inc and owns about 3,481,652 shares of Sagent Pharmaceuticals Inc (SGNT) stock worth over $76 Million. Vivo Ventures Fund Vi, L.p. is also the 10% Owner of Eiger BioPharmaceuticals Inc and owns about 59,570 shares of Eiger BioPharmaceuticals Inc (EIGRQ) stock worth over $506,345. Details can be seen in Vivo Ventures Fund Vi, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Vivo Ventures Fund Vi, L.p. has not made any transactions after 2016-08-18 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Vivo Ventures Fund Vi, L.p.
Vivo Ventures Fund Vi, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Vivo Ventures Fund Vi, L.p. owns 3 companies in total, including Eiger BioPharmaceuticals Inc (EIGRQ) , Sagent Pharmaceuticals Inc (SGNT) , and KalVista Pharmaceuticals Inc (KALV) .
Click here to see the complete history of Vivo Ventures Fund Vi, L.p.’s form 4 insider trades.
Insider Ownership Summary of Vivo Ventures Fund Vi, L.p.
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
EIGRQ | Eiger BioPharmaceuticals Inc | 2016-08-18 | 10 percent owner |
SGNT | Sagent Pharmaceuticals Inc | 2016-04-21 | 10 percent owner |
KALV | KalVista Pharmaceuticals Inc | 2015-04-08 | 10 percent owner |
Vivo Ventures Fund Vi, L.p. Latest Holdings Summary
Vivo Ventures Fund Vi, L.p. currently owns a total of 2 stocks. Among these stocks, Vivo Ventures Fund Vi, L.p. owns 3,481,652 shares of Sagent Pharmaceuticals Inc (SGNT) as of April 21, 2016, with a value of $76 Million and a weighting of 99.34%. Vivo Ventures Fund Vi, L.p. also owns 59,570 shares of Eiger BioPharmaceuticals Inc (EIGRQ) as of August 18, 2016, with a value of $506,345 and a weighting of 0.66%.
Latest Holdings of Vivo Ventures Fund Vi, L.p.
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
SGNT | Sagent Pharmaceuticals Inc | 2016-04-21 | 3,481,652 | 21.76 | 75,760,748 |
EIGRQ | Eiger BioPharmaceuticals Inc | 2016-08-18 | 59,570 | 8.50 | 506,345 |
Holding Weightings of Vivo Ventures Fund Vi, L.p.
Vivo Ventures Fund Vi, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Vivo Ventures Fund Vi, L.p. has made a total of 0 transactions in Sagent Pharmaceuticals Inc (SGNT) over the past 5 years. The most-recent trade in Sagent Pharmaceuticals Inc is the sale of 2,316 shares on April 21, 2016, which brought Vivo Ventures Fund Vi, L.p. around $31,382.
According to the SEC Form 4 filings, Vivo Ventures Fund Vi, L.p. has made a total of 0 transactions in Eiger BioPharmaceuticals Inc (EIGRQ) over the past 5 years. The most-recent trade in Eiger BioPharmaceuticals Inc is the acquisition of 6,250 shares on August 18, 2016, which cost Vivo Ventures Fund Vi, L.p. around $3 Million.
Insider Trading History of Vivo Ventures Fund Vi, L.p.
- 1
Vivo Ventures Fund Vi, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Vivo Ventures Fund Vi, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Vivo Ventures Fund Vi, L.p. is -15.29%. GuruFocus also compares Vivo Ventures Fund Vi, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Vivo Ventures Fund Vi, L.p. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Vivo Ventures Fund Vi, L.p.'s insider trading performs compared to the benchmark.
Performance of Vivo Ventures Fund Vi, L.p.
Vivo Ventures Fund Vi, L.p. Ownership Network
Ownership Network List of Vivo Ventures Fund Vi, L.p.
Ownership Network Relation of Vivo Ventures Fund Vi, L.p.
Vivo Ventures Fund Vi, L.p. Owned Company Details
What does Eiger BioPharmaceuticals Inc do?
Who are the key executives at Eiger BioPharmaceuticals Inc?
Vivo Ventures Fund Vi, L.p. is the 10 percent owner of Eiger BioPharmaceuticals Inc. Other key executives at Eiger BioPharmaceuticals Inc include 10 percent owner Richard A Kayne , 10 percent owner Leen Kawas , and Chief Business Officer Ingrid Choong .
Eiger BioPharmaceuticals Inc (EIGRQ) Insider Trades Summary
Over the past 18 months, Vivo Ventures Fund Vi, L.p. made no insider transaction in Eiger BioPharmaceuticals Inc (EIGRQ). Other recent insider transactions involving Eiger BioPharmaceuticals Inc (EIGRQ) include a net purchase of 278,239 shares made by Richard A Kayne , and a net purchase of 24,332 shares made by Leen Kawas .
In summary, during the past 3 months, insiders sold 0 shares of Eiger BioPharmaceuticals Inc (EIGRQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eiger BioPharmaceuticals Inc (EIGRQ) were sold and 10,086 shares were bought by its insiders, resulting in a net purchase of 10,086 shares.
Eiger BioPharmaceuticals Inc (EIGRQ)'s detailed insider trading history can be found in Insider Trading Tracker table.
Eiger BioPharmaceuticals Inc Insider Transactions
Vivo Ventures Fund Vi, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Vivo Ventures Fund Vi, L.p.. You might contact Vivo Ventures Fund Vi, L.p. via mailing address: 575 High Street, Suite 201, Palo Alto Ca 94301.